-
Vascular health years after a hypertensive disorder of pregnancy: The EPOCH Study Am. Heart J. (IF 4.8) Pub Date : 2024-03-12 Hayley E. Miller MD, Seda Tierney MD, Marcia L. Stefanick PhD, Jonathan A. Mayo MPH, Oshra Sedan PhD, Lisa G. Rosas MPH PhD, Mads Melbye MD DrMed, Heather A. Boyd PhD, David K. Stevenson MD, Gary M. Shaw DrPH, Virginia D. Winn MD PhD, Mark A. Hlatky MD
Preeclampsia is associated with a two-fold increase in a woman's lifetime risk of developing atherosclerotic cardiovascular disease (ASCVD), but the reasons for this association are uncertain. The objective of this study was to examine the associations between vascular health and a hypertensive disorder of pregnancy among women ≥ 2 years postpartum. Pre-menopausal women with a history of either a hypertensive
-
Rationale and design of NUDGE-FLU-CHRONIC and NUDGE-FLU-2: Two nationwide randomized trials of electronic nudges to increase influenza vaccination among patients with chronic diseases and older adults during the 2023/2024 influenza season Am. Heart J. (IF 4.8) Pub Date : 2024-03-07 Niklas Dyrby Johansen MD, Muthiah Vaduganathan MD MPH, Ankeet S. Bhatt MD MBA ScM, Daniel Modin MD, Safia Chatur MD, Brian L. Claggett PhD, Kira Hyldekær Janstrup PhD, Carsten Schade Larsen MD DMSc, Lykke Larsen MD PhD, Lothar Wiese MD PhD, Michael Dalager-Pedersen MD PhD, Lars Køber MD DMSc, Scott D. Solomon MD, Pradeesh Sivapalan MD PhD, Jens Ulrik Stæhr Jensen MD PhD, Cyril Jean-Marie Martel PhD
Yearly influenza vaccination is strongly recommended for older adults and patients with chronic diseases including cardiovascular disease (CVD); however, vaccination rates remain suboptimal, particularly among younger patients. Electronic letters incorporating behavioral nudges are highly scalable public health interventions which can potentially increase vaccination, but further research is needed
-
Effect of Patient Factors, Center, and Era on Fontan Timing: An observational study using the Pediatric Health Information Systems Database Am. Heart J. (IF 4.8) Pub Date : 2024-02-25 Bethan A Lemley MD MSCE, Oluwatimilehin Okunowo MPH, Steve B Ampah PhD, Lezhou Wu, Russell T Shinohara PhD, David J. Goldberg MD, Jack Rychik MD, Andrew C Glatz MD MSCE, Sandra Amaral MD MHS, Michael L O'Byrne MD MSCE
There are no consensus guidelines defining optimal timing for the Fontan operation, the last planned surgery in staged palliation for single-ventricle heart disease. Identify patient-level characteristics, center-level variation, and secular trends driving Fontan timing. A retrospective observational study of subjects who underwent Fontan from 2007-2021 at centers in the Pediatric Health Information
-
Transfemoral transcatheter aortic valve replacement with VitaFlowTM valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-25 Juan Zhang MD, Xiang-Quan Kong MD, Xiao-Fei Gao MD, Jing Chen MD, Xiang Chen MD, Bo Li MD, Yi-Bing Shao MD, Yan Wang MD, Hong Jiang MD, Jian-Cheng Zhu MD, Jun-Jie Zhang MD, Shao-Liang Chen MD, SEASON-AR investigators
Previous studies primarily demonstrated that transfemoral transcatheter aortic valve replacement (TAVR) with self-expanding valve appeared to be a safe and feasible treatment for patients with pure native aortic regurgitation (AR). However, the routine application of transfemoral TAVR for pure AR patients lacks support from randomized trials. SEASON-AR trial is a prospective, multicenter, randomized
-
Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-23 Sang-Hyup Lee MD, Seung-Jun Lee MD, Jung Ho Heo MD, Sung Gyun Ahn MD, Joon-Hyoung Doh MD, Sanghoon Shin MD, Jaemin Shim MD, Ae-Young Her MD, Byung Gyu Kim MD, Sang Wook Lim MD, Taek-Geun Kwon MD, Kyoung-Hoon Lee MD, Daehoon Kim MD, Yong-Joon Lee MD, Hee Tae Yu MD, Tae-Hoon Kim MD, Dong-Ho Shin MD, Hui-Nam Pak MD, Jung-Sun Kim MD
Both anticoagulation and antiplatelet therapies are recommended after percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF). Although contemporary guidelines recommend discontinuation of antiplatelet therapy 1 year after drug-eluting stent (DES) implantation due to excessive bleeding risk, supporting randomized trials are still lacking. The ADAPT AF-DES trial is a multicenter
-
Strategy to optimize PeriproCeduraL AnticOagulation in structural transseptal interventions: Design and rationale of the STOP CLOT trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-22 Jerzy Pręgowski M.D., Radosław Pracoń M.D., Aleksandra Mioduszewska M.D., Jarosław Skowroński M.D., Lars Sondergaard M.D., Gary S. Mintz M.D., Davide Capodanno M.D., Sang-Wook Kim M.D., Ole De Baker M.D., Piotr Waciński M.D., Wojciech Wojakowski M.D., Adam Rdzanek M.D., Marek Grygier M.D., Michał Chmielecki M.D., Luis Nombela Franco M.D., Patrycjusz Stokłosa M.D., Bohdan Firek M.D., Magdalena Marczak
Both transcatheter edge-to-edge repair (TEER) of mitral regurgitation or left atrial appendage closure (LAAC) require periprocedural anticoagulation with unfractionated heparin (UFH) that is administered either before or immediately after transseptal puncture (TSP). The optimal timing of UFH administration (before or after TSP) is unknown. The Strategy To Optimize PeriproCeduraL AnticOagulation in
-
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-22 James L. Januzzi Jr. MD, Yuxi Liu MS, Naveed Sattar MD PhD, Yshai Yavin MBChB, Carol A. Pollock MD, Javed Butler MD MPH MBA, Meg Jardine MBBS PhD, Hiddo J.L. Heerspink PhD PharmD, Serge Masson PhD, Matthew Breyer MD, Michael K. Hansen PhD
Circulating concentrations of vascular endothelial growth factor (VEGF) family members may be abnormally elevated in type 2 diabetes (T2D). The roles of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFLT-1), and VEGF-A in cardio-renal complications of T2D are not established. The 2602 individuals with diabetic kidney disease (DKD) from the Canagliflozin and Renal Events in Diabetes
-
Plasma proteomics for prediction of subclinical coronary artery calcifications in primary prevention Am. Heart J. (IF 4.8) Pub Date : 2024-02-05 Patrick Royer MD, Elias Björnson PhD, Martin Adiels PhD, María Bueno Álvez PhD, Linn Fagerberg PhD, Fredrik Bäckhed PhD, Mathias Uhlén PhD, Anders Gummesson MD PhD, Göran Bergström MD PhD
Recent developments in high-throughput proteomic technologies enable the discovery of novel biomarkers of coronary atherosclerosis. The aims of this study were to test if plasma protein subsets could detect coronary artery calcifications (CAC) in asymptomatic individuals and if they add predictive value beyond traditional risk factors. Using proximity extension assays, 1,342 plasma proteins were measured
-
TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention versus Conventional Surgical Aortic Valve Replacement and Coronary Bypass Grafting for Treatment of Patients with Aortic Valve Stenosis and Multivessel or Advanced Coronary Disease – The TransCatheter Valve and Vessels Trial (TCW Trial): Design and Rationale Am. Heart J. (IF 4.8) Pub Date : 2024-02-01 Elvin Kedhi, Andi Rroku, Rik S. Hermanides, Jan Henk Dambrink, Sandeep Singh, Jurriën Ten Berg, Dirk-Jan van Winkel, Martin Hudec, Giovanni Amoroso, Ignacio J. Amat-Santos, Martin Andreas, Rui Campante Teles, Guillaume Bonnet, Eric Van Belle, Lenard Conradi, Leen van Garsse, Wojtek Wojakowski, Vasileious Voudris, Jerzy Sacha, Pavel Cervinka, Thomas Modine
Background : Patients with severe aortic stenosis (AS) frequently present with concomitant obstructive coronary artery disease (CAD). In those, current guidelines recommend combined coronary artery bypass grafting (CABG) and surgical aortic valve replacement (SAVR) as the preferred treatment option, although this surgical approach is associated with a high rate of clinical events. Combined transcatheter
-
Regional Differences in Outcomes with Ablation Versus Drug Therapy for Atrial Fibrillation: Results from the CABANA Trial Am. Heart J. (IF 4.8) Pub Date : 2024-02-01 Riccardo Cappato, Daniel B. Mark, Adam P. Silverstein, Peter A. Noseworthy, Gianluca Bonitta, Jeanne E. Poole, Jonathan P. Piccini, Tristram D. Bahnson, Melanie R. Daniels, Hussein R. Al-Khalidi, Kerry L. Lee, Douglas L. Packer
Background The finding of unexpected variations in treatment benefits by geographic region in international clinical trials raises complex questions about the interpretation and generalizability of trial findings. We observed such geographical variations in outcome and in the effectiveness of atrial fibrillation (AF) ablation versus drug therapy in the Catheter Ablation vs Antiarrhythmic Drug Therapy
-
Variability in Guideline-Directed Medical Therapy Across Sites and Operators and Long-Term Mortality and Amputation Outcomes Risk in Patients Undergoing Peripheral Vascular Interventions Am. Heart J. (IF 4.8) Pub Date : 2024-02-01 Kim G. Smolderen, Gaëlle Romain, Jacob Cleman, Lindsey Scierka, Carlos Mena-Hurtado
Background The use of guideline-directed medical therapy (GDMT) in patients undergoing peripheral vascular interventions (PVIs) decreases the risk of death and amputation and may decrease hospital readmissions. The variability of GDMT prescription across sites and operators and the proportionality of risk is not well understood. We aimed to study the association between variability of GDMT prescription
-
Intracoronary Electrocardiogram Detects Coronary Microvascular Dysfunction and Ischemia in Patients with No Obstructive Coronary Arteries Disease Am. Heart J. (IF 4.8) Pub Date : 2024-01-25 Erdem Cevik, Ahmet Tas, Zeynep G Demirtakan, Peter Damman, Yaren Alan, Christopher J Broyd, Alp Ozcan, Duygu H Simsek, Mehmet R Sonsoz, Niels van Royen, Divaka Perera, Justin E Davies, Sabahattin Umman, Murat Sezer
-
Rationale and design of the NODE-303 study: Evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings Am. Heart J. (IF 4.8) Pub Date : 2024-01-22 James E Ip, Hanh Bui, A John Camm, Benoit Coutu, Peter A. Noseworthy, Maria Leonor Parody, Samuel F Sears, Narendra Singh, Juan Agudelo Uribe, John Vyselaar, Sarah Omodele, Silvia Shardonofsky, David B. Bharucha, Bruce Stambler
Paroxysmal supraventricular tachycardia (PSVT) is a common episodic arrhythmia characterized by unpredictable onset and burdensome symptoms including palpitations, dizziness, chest pain, distress, and shortness of breath. Treatment of acute episodes of PSVT in the clinical setting consists of intravenous adenosine, beta-blockers, and calcium channel blockers (CCBs). Etripamil is an intranasally self-administered
-
Radial Artery versus Right Internal Mammary Artery as a Second Conduit during Coronary Artery Bypass Grafting Am. Heart J. (IF 4.8) Pub Date : 2024-01-20 Eishan Ashwat, James A. Brown, Sarah Yousef, Danial Ahmad, Yisi Wang, Floyd W. Thoma, Derek Serna-Gallegos, Pyongsoo Yoon, David West, Danny Chu, Johannes Bonatti, David Kaczorowski, Ibrahim Sultan
Objective To compare the clinical outcomes of radial artery (RA) grafts during CABG to those of right internal mammary artery (RIMA) grafts. Methods This was a retrospective, single-institution cohort study of isolated CABG with multiple grafts between 2010-2022. To balance graft cohorts, propensity score matching (PSM) was performed using a 1:1 match ratio. Long-term postoperative survival was compared
-
Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial Am. Heart J. (IF 4.8) Pub Date : 2024-01-20 Nidal Jammoul, Valentin Dupasquier, Mariama Akodad, Pierre-Alain Meunier, Lionel Moulis, Sonia Soltani, Jean-Christophe Macia, Pierre Robert, Laurent Schmutz, Matthieu Steinecker, Christophe Piot, Frederic Targosz, Henri Benkemoun, Benoît Lattuca, François Roubille, Guillaume Cayla, Florence Leclercq
Background Safety and feasibility of transcatheter aortic valve replacement (TAVR) without balloon aortic valvuloplasty (BAV) using the SAPIEN 3 balloon-expandable device has been previously demonstrated. The impact on long-term valve hemodynamic performances and outcomes remains however unknown. We evaluate long-term clinical and hemodynamic results according to the implant strategy (direct TAVR versus
-
Drug development for major chronic health conditions – aligning with growing public health needs: Proceedings from a multi-stakeholder think tank Am. Heart J. (IF 4.8) Pub Date : 2024-01-17 Konstantin A. Krychtiuk, Tomas LG Andersson, Ulrike Bodesheim, Javed Butler, Lesley H Curtis, Mitchell Elkind, Adrian F. Hernandez, Christoph Hornik, Gary H Lyman, Pooja Khatri, Michael Mbagwu, Masahiro Murakami, Gwen Nichols, Lothar Roessig, Anne Quinn Young, Richard L. Schilsky, Neha Pagidipati
The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases due to more predictable development pathways and financial incentives. In contrast, drug development for major chronic health conditions that are responsible for a large part of mortality and disability worldwide is stalled. To examine the processes of novel drug development for common chronic health conditions
-
Identifying the highest risk vascular patients: Insights from the XATOA registry Am. Heart J. (IF 4.8) Pub Date : 2024-01-12 Sonia S. Anand, Victor Aboyans, Jackie Bosch, Sebastian Debus, Alain Gay, Manesh R. Patel, Kai Vogtländer, Robert C. Welsh, Uwe Zeymer, Keith A.A. Fox
Background Patients with coronary and peripheral artery disease (PAD) have a residual risk of major adverse cardiovascular and limb events despite standards of care. Among patients with coronary artery disease (CAD) and/or PAD selected for low dose rivaroxaban (2.5 mg BID) and aspirin, we sought to determine the highest risk vascular patients. Methods Xarelto pluc Acetylsalicylic acid: Treatment patterns
-
Enhancing Lifestyles in the Metabolic Syndrome (ELM) Multi-Site Behavioral Efficacy Trial. Design and Baseline Cohort Am. Heart J. (IF 4.8) Pub Date : 2024-01-10 Lynda H. Powell, Bryce T. Daniels, Betty M. Drees, Kelly Karavolos, Barbara Lohse, Kevin S Masters, Jacinda M Nicklas, Elizabeth H. Ruder, Sumihiro Suzuki, Nicole Trabold, Laura J. Zimmermann
-
Trial outcome definitions require more attention Am. Heart J. (IF 4.8) Pub Date : 2024-01-08 David Füller
Abstract not available
-
Burden of cardiometabolic risk factors and vascular health Am. Heart J. (IF 4.8) Pub Date : 2024-01-05 Carine E. Hamo, Florencia Schlamp, Kamelia Drenkova, Manila Jindal, Maja Fadzan, Adedoyin Akinlonu, Ira Goldberg, Michael S. Garshick, Jeffrey S. Berger
Background Cardiometabolic risk factors diabetes, obesity, and hypertension are highly prevalent and contribute to increased cardiovascular disease (CVD). Endothelial dysfunction precedes CVD development. The current study aimed to investigate the EC transcriptome among individuals with varying degree of cardiometabolic risk. Methods Adult participants without CVD and various degrees of cardiometabolic
-
Prognostic performance of the IABP-SHOCK II Risk Score among cardiogenic shock subtypes in the critical care cardiology trials network registry Am. Heart J. (IF 4.8) Pub Date : 2024-01-06 Carlos L. Alviar, Boyangzi K. Li, Norma M. Keller, Erin Bohula-May, Christopher Barnett, David D. Berg, James A. Burke, Sunit-Preet Chaudhry, Lori B. Daniels, Andrew P. DeFilippis, Daniel Gerber, James Horowitz, Jacob C. Jentzer, Praneeth Katrapati, Ellen Keeley, Patrick R. Lawler, Jeong-Gun Park, Shashank S. Sinha, Jeffrey Snell, Michael A. Solomon, David A. Morrow
Background Risk stratification has potential to guide triage and decision-making in cardiogenic shock (CS). We assessed the prognostic performance of the IABP-SHOCK II score, derived in Europe for acute myocardial infarct-related CS (AMI-CS), in a contemporary North American cohort, including different CS phenotypes. Methods The critical care cardiology trials network (CCCTN) coordinated by the TIMI
-
Preoperative computed tomography-imaging with patient-specific computer simulation in transcatheter aortic valve implantation: Design and rationale of the GUIDE-TAVI trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-30 Romy R.M.J.J. Hegeman, Dirk-Jan van Ginkel, Severin Laengle, Leo Timmers, Benno J.W.M. Rensing, Thomas L. de Kroon, Uday Sonker, Johannes C. Kelder, Markus Mach, Martin Andreas, Martin J. Swaans, Jurriën M. ten Berg, Patrick Klein
Background Transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with severe aortic valve stenosis, but is still associated with relatively high rates of pacemaker implantation and paravalvular regurgitation. Routine preoperative computed tomography (CT) combined with patient-specific computer modelling can predict the interaction between the TAVI device and
-
Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-29 Erin A. Bohula, Nicholas A. Marston, Andrea Ruzza, Sabina A. Murphy, Gaetano M. De Ferrari, Rafael Diaz, Lawrence A. Leiter, Mary Elliott-Davey, Huei Wang, Ajay K. Bhatia, Robert P. Giugliano, Marc S. Sabatine
-
Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI Am. Heart J. (IF 4.8) Pub Date : 2023-12-26 Arsalan Abu-Much, Cindy L. Grines, Wayne B. Batchelor, Aneel S. Maini, Yiran Zhang, Björn Redfors, Lavanya Bellumkonda, Aditya S. Bharadwaj, Jeffrey W. Moses, Alexander G. Truesdell, Yanru Li, Suzanne J. Baron, Alexandra J. Lansky, Mir B. Basir, David J. Cohen, William W. O'Neill
-
Overview of the 2023 FDA Circulatory System Devices Advisory Panel Meeting on the Symplicity Spyral Renal Denervation System Am. Heart J. (IF 4.8) Pub Date : 2023-12-20 Kalyan R. Chitturi, Dan Haberman, Jason P. Wermers, Ron Waksman
Hypertension remains a leading preventable cause of myocardial infarction, stroke, kidney disease, and cardiovascular death worldwide. Despite lifestyle modifications and intensification of medical therapy, suboptimal blood pressure control is common, spurring the development of device-based therapies for hypertension. The US Food and Drug Administration (FDA) assembled the Circulatory System Devices
-
Effects of trimetazidine on cardiac function in adult cyanotic congenital heart disease patients: Protocol for a 3-month multicenter, randomized, double-blind controlled trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-20 Yi Shen, Li Xiang, Yifan Zhu, Chenyu Jiang, Xingliang Zhou, Xu Huang, Liwei Wu, Bei Feng, Yi Yan, Yiwei Liu, Hao Zhang
Background Nearly 20% Patients with cyanotic congenital heart disease (CCHD) are not able to receive surgery. These patients experience a decline in cardiac function as they age, which has been demonstrated to be associated with changes in energy metabolism in cardiomyocytes. Trimetazidine (TMZ), a metabolic regulator, is supposed to alleviate such maladaptation and reserve cardiac function in CCHD
-
Low- or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR: A prespecified analysis of randomized ADAPT-TAVR trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-18 Mijin Kim, Jung-Min Ahn, Do-Yoon Kang, Min-Ju Kim, Kyung Won Kim, Hyun Jung Koo, Dong Hyun Yang, Seung Chai Jung, Byungjun Kim, Yiu Tung Anthony Wong, Cheung Chi Simon Lam, Wei‐Hsian Yin, Jeng Wei, Yung-Tsai Lee, Hsien-Li Kao, Mao-Shin Lin, Tsung Yu Ko, Won-Jang Kim, Se Hun Kang, Seung-Ah Lee, Duk-Woo Park
-
Feasibility of double-blinded, placebo-controlled interventional study for assessing catheter ablation efficacy in persistent atrial fibrillation: Insights from the ORBITA AF feasibility study Am. Heart J. (IF 4.8) Pub Date : 2023-12-17 Vijayabharathy Kanthasamy, Richard Schilling, Olivier Zongo, Kamran Khan, Mark Earley, Vivienne Monk, Ross Hunter, Valentina Mangiafico, Richard Ang, Antonio Creta, Nikhil Aluwhalia, Shohreh Honarbakhsh, Mehul Dhinoja, Dhiraj Gupta, Malcolm Finlay
-
The prognostic significance of single-lead ST-segment resolution in ST-segment elevation myocardial infarction patients treated with primary PCI – A substudy of the randomized TOTAL trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Marko Sirén, Joonas Leivo, Eero Anttonen, Sanjit S. Jolly, Vladimir Dzavik, Jyri Koivumäki, Minna Tahvanainen, Kimmo Koivula, Jia Wang, John A. Cairns, Kari Niemelä, Markku Eskola, Kjell C. Nikus, Jussi Hernesniemi
BACKGROUND ST-segment elevation myocardial infarction (STEMI) is associated with high morbidity and mortality worldwide. Simple electrocardiogram (ECG) tools, including ST-segment resolution (STR) have been developed to identify high-risk STEMI patients after primary percutaneous coronary intervention (PCI). SUBJECTS AND METHODS We evaluated the prognostic impact of STR in the ECG lead with maximal
-
Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Faizan Mazhar, Paul Hjemdahl, Arvid Sjölander, Thomas Kahan, Tomas Jernberg, Juan Jesus Carrero
Background The effectiveness of lipid-lowering therapy (LLT) for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in routine care may depend on treatment intensity and adherence. Methods Observational study of adults with newly initiated LLT for primary prevention of ASCVD in Stockholm, Sweden, during 2017-2021. Study exposures were LLT adherence [proportion of days covered (PDC)]
-
Sex-specific heart failure burden across the United States: Global burden of disease 1990-2019 Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Pedro RVO Salerno, Zhuo Chen, Sojin Wass, Issam Motairek, Chantal Elamm, Lúcia MVO Salerno, Neda Shafiabadi Hassani, Salil V. Deo, Sadeer G Al-Kindi
-
Study design and rationale of COMPETE: Comparison of the effect of medication therapy in alleviating migraine with patent foramen ovale Am. Heart J. (IF 4.8) Pub Date : 2023-12-16 Ziping Li, Jie Dong, Yiming Yan, Fang Fang, Chuangshi Wang, Fengwen Zhang, Wenbin Ouyang, Shouzheng Wang, Xiangbin Pan
Background Previous studies have examined the impact of antithrombotic agents on Patent Foramen Ovale (PFO) in relation to migraine. However, differences in effectiveness of different antithrombotic agents and traditional migraine medications are not known. Methods/Design This study is an investigator-initiated, randomized, multicenter, single-masked (outcomes assessor), and active-controlled parallel-group
-
Study of heart function in PRE-Eclampsia during and after PreGnancy (SHePREG): The pilot cohort Am. Heart J. (IF 4.8) Pub Date : 2023-12-14 Marwan Ma'ayeh, Omer Cavus, Lauren J. Hassen, Martin Johnson, Taryn Summerfield, Mosammat Begom, Amanda Cai, Laxmi Mehta, Kara Rood, Elisa A. Bradley
-
Integrating Cost into Shared Decision-Making for Heart Failure with Reduced Ejection Fraction (POCKET-COST-HF): A Trial Providing Out-of-Pocket Costs for Heart Failure Medications during Clinical Encounters Am. Heart J. (IF 4.8) Pub Date : 2023-12-12 Sarah C. Montembeau, Birju R. Rao, Andrea R. Mitchell, Candace D. Speight, Larry A. Allen, Scott D. Halpern, Yi-An Ko, Daniel D. Matlock, Miranda A. Moore, Alanna A. Morris, Laura D. Scherer, Peter Ubel, Neal W. Dickert
Background Evidence-based medical therapy for heart failure with reduced ejection fraction (HFrEF) often entails substantial out-of-pocket costs that can vary appreciably between patients. This has raised concerns regarding financial toxicity, equity, and adherence to medical therapy. In spite of these concerns, cost discussions in the HFrEF population appear to be rare, partly because out-of-pocket
-
Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries Am. Heart J. (IF 4.8) Pub Date : 2023-12-10 Matthew R. Reynolds, Rod Passman, Jason Swindle, Iman Mohammadi, Brent Wright, Kenneth Boyle, Mintu P. Turakhia, Suneet Mittal
Background Objective data comparing the diagnostic performance of different ambulatory cardiac monitors (ACMs) are lacking. Objectives To assess variation in monitoring strategy, clinical outcomes and healthcare utilization in patients undergoing ambulatory monitoring without a pre-existing arrhythmia diagnosis. Methods Using the full sample (100%) of Medicare claims data, we performed a retrospective
-
NatIonal Danish endocarditis stUdieS – Design and objectives of the NIDUS registry Am. Heart J. (IF 4.8) Pub Date : 2023-12-04 Peter L. Graversen, Katra Hadji-Turdeghal, Jacob Eifer Møller, Niels Eske Bruun, Hicham Laghmoch, Andreas Dalsgaard Jensen, Jeppe K. Petersen, Henning Bundgaard, Kasper Iversen, Jonas A Povlsen, Claus Moser, Morten Smerup, Hanne Sortsøe Jensen, Peter Søgaard, Jannik Helweg-Larsen, Daniel Faurholt-Jepsen, Lauge Østergaard, Lars Køber, Emil L. Fosbøl
Aims The National Danish endocarditis stUdieS (NIDUS) registry aims to investigate the mechanisms contributing to the increasing incidence of IE and to discover risk factors associated to the course, treatment and clinical outcomes of the disease. Methods The NIDUS registry was created to investigate a nationwide unselected group of patients hospitalized for infective endocarditis (IE). The National
-
Design and Rationale of the Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis: The EARLY TAVR Trial Am. Heart J. (IF 4.8) Pub Date : 2023-12-04 Philippe Généreux, Allan Schwartz, Brad Oldemeyer, David J. Cohen, Björn Redfors, Heather Prince, Yanglu Zhao, Brian R. Lindman, Philippe Pibarot, Martin B. Leon
Background For patients with asymptomatic, severe aortic stenosis (AS) and preserved left ventricular ejection fraction, current guidelines recommend clinical surveillance every 6 to 12 months. To date, no randomized trials have examined whether an early intervention with transcatheter aortic valve replacement (TAVR) will improve outcomes among these patients. Study Design and Objectives EARLY TAVR
-
Costs of care and financial hardship among patients with heart failure Am. Heart J. (IF 4.8) Pub Date : 2023-12-06 Alexander H. Gunn, Haider J. Warraich, Robert J. Mentz
With the implementation of new therapies, more patients are living with heart failure (HF) as a chronic condition. Alongside these advances, out-of-pocket (OOP) medical costs have increased, and patients experience significant financial burden. Despite increasing interest in understanding and mitigating financial burdens, there is a relative paucity of data specific to HF. Here, we explore financial
-
Regionalization of stroke systems of care in the stroke belt states: The IMPROVE stroke care quality improvement program Am. Heart J. (IF 4.8) Pub Date : 2023-12-05 Brad J. Kolls, Matthew E. Ehrlich, Lisa Monk, Shreyansh Shah, Mayme Roettig, Edwin Iversen, James G. Jollis, Christopher B. Granger, Carmelo Graffagnino
Background Despite guidelines and strong evidence supporting intravenous thrombolysis and endovascular thrombectomy for acute stroke, access to these interventions remains a challenge. The objective of the IMPROVE stroke care program was to accelerate acute stroke care delivery by implementing best practices and improving the regional systems of care within comprehensive stroke networks. Methods The
-
High prevalence and distinctive clinical features of LMNA-associated atrioventricular block in young patients Am. Heart J. (IF 4.8) Pub Date : 2023-12-03 Xin Chen, Guanhao Luo, Hezhi Li, Jianhong Zheng, Qianhuan Zhang, Hongtao Liao, Xianzhang Zhan, Wei Wei, Yuanhong Liang, Hai Deng, Xianhong Fang, Shulin Wu, Yumei Xue, Yang Liu
Background and aims Atrioventricular block (AVB) is a degenerative disease and more commonly encountered in elderly patients, but unusual and often of unknown etiology in young patients. This study aimed to investigate the potential contributions of genetic variations to AVB of unknown reasons in young patients. Methods We enrolled 41 patients aged <55 years with high-degree AVB of unknown etiology
-
External Validation of the 0/1h-Algorithm and Derivation of a 0/2h-Algorithm using a New Point-of-Care Hs-cTnI Assay Am. Heart J. (IF 4.8) Pub Date : 2023-12-01 Luca Koechlin, Jasper Boeddinghaus, Pedro Lopez-Ayala, Karin Wildi, Thomas Nestelberger, Desiree Wussler, Caroline A. Guzman Tacla, Timothy Holder, Tamar Muench-Gerber, Jonas Glaeser, Ana Yufera Sanchez, Òscar Miró, F. Javier Martin-Sanchez, Damian Kawecki, Franz Buergler, Andreas Buser, Gabrielle Huré, Maria Rubini Giménez, Dagmar I. Keller, Michael Christ, Christian Mueller
-
Symptom burden guiding invasive electrophysiological study in paroxysmal supraventricular tachycardia: The believe SVT registry Am. Heart J. (IF 4.8) Pub Date : 2023-12-01 Daniel Rodriguez Muñoz, Javier Ramos Jimenez, Álvaro Marco Del Castillo, Cristina Lozano Granero, Arcadio García Alberola, Diego Jiménez Sánchez, Clara Guntúriz Beltrán, Pablo Ramos Ruiz, Miguel Ángel Arias, Bruna Di Nubila, Andrés Betancur, Esteban González Torrecilla, Paolo Dallaglio, Pau Alonso Fernández, Hebert David Ayala More, Sofía Calero, Giuseppe Lumia, Ricardo Salgado Aranda, Carla Lázaro
-
Rationale and design of the VAST-AF trial: A randomized controlled, blinded, clinical trial to evaluate transcutaneous vagal nerve stimulation for the prevention of persistent atrial fibrillation recurrence Am. Heart J. (IF 4.8) Pub Date : 2023-11-30 Patrick Swojanowsky, Marija Bundis-Dimitrijevic, Chung Shing Rex Ha, Hubertus von Korn
Background Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and is linked to significant symptoms and an elevated risk of heart failure, thromboembolism and disabling stroke. Not only do patients suffer from AF and the concomitant complications, but it is a great economic burden for healthcare systems all over the world. Despite remarkable progress in the field of AF, the basic mechanisms
-
Effects of intensive blood pressure control on left ventricular hypertrophy in aortic valve disease Am. Heart J. (IF 4.8) Pub Date : 2023-11-23 Mijin Kim, Jung-Hyun Choi, Hyung-Kwan Kim, Hack-Lyoung Kim, Sung-Hee Shin, Jeong-Yoon Jang, Jae-Hyung Park, Kye-Hun Kim, Geu-Ru Hong, Seong-Mi Park, Seung-Ah Lee, Duk-Hyun Kang
-
Benefit of cardiac resynchronization therapy among older patients: a patient-level meta-analysis: Short title: CRT in older patients: patient level meta analysis Am. Heart J. (IF 4.8) Pub Date : 2023-11-19 Emily P. Zeitler, Frederik Dalgaard, William T. Abraham, John G.F. Cleland, Anne B. Curtis, Daniel J. Friedman, Michael R. Gold, Valentina Kutyifa, Cecilia Linde, Anthony S. Tang, Antonio Olivas-Martinez, Lurdes Y.T. Inoue, Gillian D. Sanders, Sana M. Al-Khatib
Background Cardiac resynchronization therapy (CRT) reduces heart failure hospitalizations (HFH) and mortality for guideline-indicated patients with heart failure (HF). Most patients with HF are aged ≥70 years but such patients are often under-represented in randomized trials. Methods Patient-level data were combined from 8 randomized trials published 2002-2013 comparing CRT to no CRT (n=6369). The
-
Association of admission serum sodium and outcomes following out-of-hospital cardiac arrest Am. Heart J. (IF 4.8) Pub Date : 2023-11-20 Si Cong Ye, Christopher C. Cheung, Erik Lauder, Brian Grunau, Nima Moghaddam, Sean van Diepen, Daniel T. Holmes, Mypinder S. Sekhon, Jim Christenson, John M. Tallon, Christopher B. Fordyce
Background The prognostic association between dysnatremia and outcomes in out-of-hospital cardiac arrest (OHCA) is not well understood. Given hypernatremia is associated with poor outcomes in critical illness and hyponatremia may exacerbate cerebral edema, we hypothesized that dysnatremia on OHCA hospital admission would be associated with worse neurological outcomes. Methods We studied adults (≥19
-
Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure Am. Heart J. (IF 4.8) Pub Date : 2023-11-15 Gianluigi Savarese, Paolo Gatti, Lina Benson, Marianna Adamo, Ovidiu Chioncel, Maria G. Crespo-Leiro, Stefan D. Anker, Andrew J.S. Coats, Gerasimos Filippatos, Mitja Lainscak, Theresa McDonagh, Alexandre Mebazaa, Marco Metra, Massimo F. Piepoli, Giuseppe M.C. Rosano, Frank Ruschitzka, Petar Seferovic, Maurizio Volterrani, Aldo P. Maggioni, Lars H. Lund
-
High-risk admission prior to transcatheter aortic valve replacement and subsequent outcomes Am. Heart J. (IF 4.8) Pub Date : 2023-11-14 Jarl Emanuel Strange, Nina Nouhravesh, Morten Schou, Daniel Mølager Christensen, Anders Holt, Lauge Østergaard, Lars Køber, Jonas Bjerring Olesen, Emil Loldrup Fosbøl
-
Testing interventions to reduce clinical inertia in the treatment of hypertension: rationale and design of a pragmatic randomized controlled trial Am. Heart J. (IF 4.8) Pub Date : 2023-11-14 Nancy Haff, Sushama Kattinakere Sreedhara, Wendy Wood, Elad Yom-Tov, Daniel M Horn, Melissa Hoover, Greg Low, Julie C. Lauffenburger, Alexander Chaitoff, Massimiliano Russo, Kaitlin Hanken, Katherine L. Crum, Constance P. Fontanet, Niteesh K. Choudhry
Background Clinical inertia, or failure to intensify treatment when indicated, leads to suboptimal blood pressure control. Interventions to overcome inertia and increase antihypertensive prescribing have been modestly successful in part because their effectiveness varies based on characteristics of the provider, the patient, or the provider-patient interaction. Understanding for whom each intervention
-
Trends in mortality risk of patients with congenital heart disease during the COVID-19 pandemic Am. Heart J. (IF 4.8) Pub Date : 2023-11-14 Yanxu Yang, Kristina Kuo, J'Neka S. Claxton, Jessica H. Knight, Yijian Huang, Matthew E. Oster, Lazaros K. Kochilas
-
Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non-vaccine-associated myocarditis within the prospective multi-center registry - “MYKKE”: Short Title: Pediatric COVID-19 vaccine-associated myocarditis Am. Heart J. (IF 4.8) Pub Date : 2023-11-11 Nele Rolfs, Cynthia Huber, Eicke Schwarzkopf, Dirk Mentzer, B Keller-Stanislawski, Bernd Opgen-Rhein, Wiebke Frede, Axel Rentzsch, Tobias Hecht, Martin Boehne, Maria Grafmann, Daniela Kiski, Iva Graumann, Rudi Foth, Inga Voges, Ulrich Schweigmann, Bettina Ruf, Marcus Fischer, Gesa Wiegand, Karin Klingel, Franziska Seidel
Background Since the onset of widespread COVID-19 vaccination, increased incidence of COVID-19 vaccine-associated myocarditis (VA-myocarditis) has been noted, particularly in male adolescents. Methods Patients <18 years with suspected myocarditis following COVID-19 vaccination within 21 days were enrolled in the PedMYCVAC cohort, a substudy within the prospective multi-center registry for pediatric
-
Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021 Am. Heart J. (IF 4.8) Pub Date : 2023-11-11 Taufiq Salahuddin, Annika Hebbe, Marguerite Daus, Utibe R. Essien, Stephen W. Waldo, Fatima Rodriguez, P. Michael Ho, Carol Simons, Heather M. Gilmartin, Jacob A. Doll
Background We assessed trends in novel cardiovascular medication utilization in US Veterans Affairs (VA) for angiotensin receptor-neprilysin inhibitors (ARNI), sodium-glucose cotransporter-2 Inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RA). Methods We retrospectively identified cohorts from 114 VA hospitals with admission for prevalent 1) systolic heart failure (HF, N = 82
-
Influenza vaccination and use of lipid lowering therapies in adults with atherosclerotic cardiovascular disease: An analysis of the Behavioral Risk Factor Surveillance System (BRFSS) Am. Heart J. (IF 4.8) Pub Date : 2023-11-11 Samuel D. Slavin, Adam N. Berman, Prakriti Gaba, Rosangela A. Hoshi, Murray A. Mittleman
-
Opioid prescription and risk of atrial fibrillation in younger veterans Am. Heart J. (IF 4.8) Pub Date : 2023-11-09 Philip W. Chui, Arshjot Khokhar, Kirsha S. Gordon, James Dziura, Matthew M. Burg, Cynthia Brandt, Sally G. Haskell, Brian Malm, Lori A. Bastian, Parul U. Gandhi
Background Opioids may play a part in the development of atrial fibrillation (AF). Understanding the relationship between opioid exposure and AF can help providers better assess the risk and benefits of prescribing opioids. Objective To assess the incidence of AF as a function of prescribed opioids and opioid type. Design We performed unadjusted and adjusted time-updated Cox regressions to assess the
-
Realtime Diagnosis from Electrocardiogram Artificial Intelligence-Guided Screening for Atrial Fibrillation with Long Follow-Up (REGAL): Rationale and design of a pragmatic, decentralized, randomized controlled trial Am. Heart J. (IF 4.8) Pub Date : 2023-10-30 Xiaoxi Yao, Zachi I. Attia, Emma M. Behnken, Melissa S. Hart, Shealeigh A. Inselman, Kayla C. Weber, Fan Li, Nikki H. Stricker, John L. Stricker, Paul A. Friedman, Peter A. Noseworthy
Background Atrial fibrillation (AF) is associated with increased risks of stroke and dementia. Early diagnosis and treatment could reduce the disease burden, but AF is often undiagnosed. An artificial intelligence (AI) algorithm has been shown to identify patients with previously unrecognized AF; however, monitoring these high-risk patients has been challenging. Consumer wearable devices could be an
-
Cardiovascular impact of near complete estrogen deprivation in premenopausal women with breast cancer: The CROWN study Am. Heart J. (IF 4.8) Pub Date : 2023-10-26 Alexandra Thomas, Nathaniel S. O'Connell, Emily Douglas, Sarah Hatcher, Carolyn J. Park, Susan Dent, Katherine Ansley, Igor Klem, Rani Bansal, Kelly Westbrook, W. Gregory Hundley, Wendy Bottinor, Mary Helen Hackney, Karl M. Richardson, Sherona R. Sirkisoon, Ralph B. D'Agostino, Jennifer H. Jordan
Survival with operable breast cancer has improved markedly in recent decades, however, treatment-related cardiovascular toxicities threaten to offset these gains. Ovarian function suppression paired with aromatase inhibition, for premenopausal women with hormone receptor (HR)-positive breast cancer, is a newer widely adopted therapy with the potential for significant long-term cardiovascular toxicity
-
Effects of complete revascularization according to age in patients with ST-segment elevation myocardial infarction and multivessel disease (COMPLETE-AGE) Am. Heart J. (IF 4.8) Pub Date : 2023-10-21 Kevin R. Bainey, David A. Wood, Matthias Bossard, Gianluca Campo, Warren J. Cantor, Shahar Lavi, Mina Madan, Roxana Mehran, Natalia Pinilla-Echeverri, Sunil Rao, Jaydeep Sarma, Tej Sheth, Goran Stankovic, Phillipe Gabriel Steg, Robert F. Storey, Jean-Francois Tanguay, James L. Velianou, Robert C. Welsh, Thenmozhi Mani, John A. Cairns, Shamir R. Mehta
Background In ST-segment elevation myocardial infarction (STEMI), complete revascularization with percutaneous coronary intervention (PCI) reduces major cardiovascular events compared with culprit-lesion-only PCI. Whether age influences these results remains unknown. Methods COMPLETE was a multinational, randomized trial evaluating a strategy of staged complete revascularization, consisting of angiography-guided
-
A randomized trial of expedited intra-arrest transfer versus more extended on-scene resuscitation for refractory out of hospital cardiac arrest: Rationale and design of the EVIDENCE trial Am. Heart J. (IF 4.8) Pub Date : 2023-10-21 Brian Burns, Ian Marschner, Renee Eggins, Hergen Buscher, Rachael L. Morton, Jason Bendall, Anthony Keech, Mark Dennis
Background Refractory Out of Hospital Cardiac Arrest (r-OHCA) is common and the benefit versus harm of intra-arrest transport of patients to hospital is not clear. Objective To assess the rate of survival to hospital discharge in adult patients with r-OHCA, initial rhythm pulseless ventricular tachycardia (VT)/ventricular fibrillation (VF) or Pulseless Electrical Activity (PEA) treated with 1 of 2
-
Long-term risk of reintervention after transcatheter aortic valve replacement Am. Heart J. (IF 4.8) Pub Date : 2023-10-21 Suzanne J. Baron, Michael P. Ryan, Soumya G. Chikermane, Christin Thompson, Seth Clancy, Candace L. Gunnarsson
Background Transcatheter aortic valve replacement (TAVR) has surpassed surgical aortic valve replacement (SAVR) as the predominant mode of valve replacement for the treatment of severe aortic stenosis (AS). However, the long-term need for valvular reintervention after TAVR remains unknown. Methods Using data from the Medicare Fee for Service 100% dataset, all patients receiving TAVR between July 2011
-
Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials Am. Heart J. (IF 4.8) Pub Date : 2023-10-11 Tino Severinsen, Jens Jakob Thune, Helga Lillian Gudmundsdottir, Christoffer Rasmus Vissing, Kasper Iversen, Carolyn Yung Ho, Henning Bundgaard, Anna Axelsson Raja
Purpose To identify the cause of discrepancy between the INHERIT trial and VANISH trial in regards to disease modification of angiotensin receptor II blockers in hypertrophic cardiomyopathy (HCM). Methods We replicated the data analysis used in VANISH, converting individual change in each component of the composite endpoint into a z-score and applying this z-score to the INHERIT results. Results No